214 related articles for article (PubMed ID: 8683314)
1. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
[TBL] [Abstract][Full Text] [Related]
2. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
5. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
[TBL] [Abstract][Full Text] [Related]
6. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Schelling M; Avril N; Nährig J; Kuhn W; Römer W; Sattler D; Werner M; Dose J; Jänicke F; Graeff H; Schwaiger M
J Clin Oncol; 2000 Apr; 18(8):1689-95. PubMed ID: 10764429
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
[TBL] [Abstract][Full Text] [Related]
10. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
11. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Schwarz-Dose J; Untch M; Tiling R; Sassen S; Mahner S; Kahlert S; Harbeck N; Lebeau A; Brenner W; Schwaiger M; Jaenicke F; Avril N
J Clin Oncol; 2009 Feb; 27(4):535-41. PubMed ID: 19075273
[TBL] [Abstract][Full Text] [Related]
12. Detecting recurrent or residual lung cancer with FDG-PET.
Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?
Jansson T; Westlin JE; Ahlström H; Lilja A; Långström B; Bergh J
J Clin Oncol; 1995 Jun; 13(6):1470-7. PubMed ID: 7751894
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.
Avril N; Dose J; Jänicke F; Bense S; Ziegler S; Laubenbacher C; Römer W; Pache H; Herz M; Allgayer B; Nathrath W; Graeff H; Schwaiger M
J Clin Oncol; 1996 Jun; 14(6):1848-57. PubMed ID: 8656253
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
16. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
[TBL] [Abstract][Full Text] [Related]
17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Helvie MA; Joynt LK; Cody RL; Pierce LJ; Adler DD; Merajver SD
Radiology; 1996 Feb; 198(2):327-32. PubMed ID: 8596826
[TBL] [Abstract][Full Text] [Related]
20. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
